학술논문
A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.
Document Type
Article
Author
Source
Investigational New Drugs; Feb2017, Vol. 35 Issue 1, p68-78, 11p
Subject
Language
ISSN
01676997